Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

Mucous Membrane Pemphigoid Clinical Trial

Official title: Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

Status Terminated

Clinical Trial Summary

Ocular mucous membrane pemphigoid (MMP) is an autoimmune, scarring conjunctivitis that can lead to vision loss and permanent disability. It is a rare disorder with an estimated incidence of 1 in 60,000. There are currently no FDA-approved medications for the treatment of mucous membrane pemphigoid, highlighting a clear unmet need. At present, moderate to severe disease requires off-label use of potent immunosuppressive agents, such as oral anti-proliferatives (methotrexate, azathioprine, and mycophenolate), rituximab (RTX) or cyclophosphamide (CyC). Recently, Janus kinase (JAK) inhibition with baricitinib or tofacitinib been reported to be successful in one case of ocular MMP. This is a randomized, single-masked, two-arm study of baricitinib vs anti-proliferatives for ocular MMP.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Cicatrizing Conjunctivitis
• Conjunctivitis
• Mucous Membrane Pemphigoid
• Pemphigoid, Bullous

• NCT number: NCT05263505
• Study type: Interventional
• Source: Washington University School of Medicine
• Status: Terminated
• Phase: Phase 2
• Start date: February 21, 2022
• Completion date: September 11, 2023